CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Citalopram",CYP2C19,Major – significant result that may require altering this medication
"Rabeprazole",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"hydroxychloroquine, levothyroxine sodium (Levothyroxine Sodium For Injection), mesalazine, zopiclone",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,FDA2
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG3
"",Propafenone,CYP2D6,Adverse effects,DPWG3
"Anticholinergics(genitourinary)",Tolterodine,CYP2D6,Adverse effects,FDA4
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Significantly increasedacenocoumarol sensitivity",DPWG
"",Warfarin,"VKORC1CYP2C9","Significantly increased warfarinsensitivity",FDA5
"Antidepressants -other",Vortioxetine,CYP2D6,Adverse effects,"TGA6, FDA7"
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Venlafaxine,CYP2D6,Adverse effects,DPWG3
"Antidepressants -SSRIs",Citalopram,CYP2C19,Reduced / inadequate response,CPIC1
Escitalopram,CYP2C19,Reduced / inadequate response,CPIC1,
Fluoxetine,"CYP2D6CYP2C9",Adverse effects,FDA8,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Fluvoxamine,"CYP2D6CYP1A2",Adverse effects,CPIC1
"",Paroxetine,CYP2D6,Adverse effects,CPIC1
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Altered response,CPIC9
"",Clomipramine,"CYP2D6CYP2C19",Altered response,CPIC9
"",Desipramine,CYP2D6,Adverse effects,CPIC9
"",Doxepin,"CYP2D6CYP2C19",Altered response,CPIC9
"",Imipramine,"CYP2D6CYP2C19",Altered response,CPIC9
"",Nortriptyline,CYP2D6,Adverse effects,CPIC9
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC10
Antiepileptics,Phenytoin,CYP2C9,Adverse effects,CPIC11
Antifungals - Azoles,Voriconazole,CYP2C19,Reduced / inadequate response,CPIC12
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,"DPWG3,TGA13, FDA14"
"",Brexpiprazole,CYP2D6,Adverse effects,FDA15
"",Haloperidol,CYP2D6,Adverse effects,DPWG
"",Pimozide,CYP2D6,Adverse effects,FDA16
"",Risperidone,CYP2D6,Adverse effects,DPWG3
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG3
Antitussives,Dextromethorphan,CYP2D6,Adverse effects,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG3
"Glaucoma - ocularpreparations",Timolol,CYP2D6,Adverse effects,-
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC17
Miscellaneous,Eliglustat,CYP2D6,Adverse effects,TGA18
Neurological drugs,Tetrabenazine,CYP2D6,"Increased therapeutic andadverse effects",FDA19
Opioid Analgesics,Codeine,"CYP2D6OPRM1",Reduced / inadequate response,CPIC20
Hydrocodone,CYP2D6,Reduced / inadequate response,,
Tramadol,CYP2D6,Reduced / inadequate response,DPWG3,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"Increased therapeutic and/oradverse effects",-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,Adverse effects,-
"",Fesoterodine,CYP2D6,Adverse effects,-
Anticholinesterases,Donepezil,CYP2D6,Adverse effects,-
"",Galantamine,CYP2D6,Adverse effects,-
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Altered response,-
Moclobemide,CYP2C19,Reduced / inadequate response,-,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"Antidepressants -SSRIs",Sertraline,CYP2C19,Reduced / inadequate response,CPIC1
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
"",Glimepiride,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Glyburide,CYP2C9,"Increased therapeutic and/oradverse effects",-
Antiemetics,Metoclopramide,CYP2D6,Adverse effects,-
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
"",Promethazine,CYP2D6,Adverse effects,-
Antiplatelet drugs,Clopidogrel,CYP2C19,Adverse effects,CPIC21
Antipsychotics,Chlorpromazine,CYP2D6,Adverse effects,-
"",Clozapine,CYP1A2,Reduced / inadequate response,-
"",Olanzapine,CYP1A2,Reduced / inadequate response,-
Benzodiazepines,Clobazam,CYP2C19,Reduced / inadequate response,-
"",Diazepam,CYP2C19,Reduced / inadequate response,-
Beta blockers,Carvedilol,CYP2D6,Adverse effects,-
"",Nebivolol,CYP2D6,Adverse effects,-
"",Propranolol,"CYP2D6CYP1A2",Altered response,-
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
Miscellaneous,Cyclophosphamide,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Altered response,-
NSAIDs,Celecoxib,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Flurbiprofen,CYP2C9,Adverse effects,-
"",Ibuprofen,CYP2C9,Adverse effects,-
"",Meloxicam,CYP2C9,Adverse effects,-
"",Piroxicam,CYP2C9,Adverse effects,-
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"",Oxycodone,CYP2D6,Reduced / inadequate response,DPWG3
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,Reduced / inadequate response,-
"",Esomeprazole,CYP2C19,Reduced / inadequate response,-
"",Lansoprazole,CYP2C19,Reduced / inadequate response,-
"",Omeprazole,CYP2C19,Reduced / inadequate response,-
"",Pantoprazole,CYP2C19,Reduced / inadequate response,-
"",Rabeprazole,CYP2C19,Reduced / inadequate response,-
Psychostimulants,Dextroamphetamine,CYP2D6,Adverse effects,-
Lisdexamfetamine,CYP2D6,Adverse effects,-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
Antipsychotics,Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC22
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
NSAIDs,Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC23,
